Borg, David <br/><br/>
Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.  [electronic resource] 

 -  Journal of translational medicine  10 2018 
 - 290 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1479-5876 
<br/><br/><label>Standard No.: </label>10.1186/s12967-018-1668-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Aged<br/>Biomarkers, Tumor--metabolism<br/>Chemotherapy, Adjuvant<br/>Cohort Studies<br/>Esophageal Neoplasms--drug therapy<br/>Female<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Prognosis<br/>Sialoglycoproteins--metabolism<br/>Stomach Neoplasms--drug therapy